On Tuesday shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) closed at $12.82. Akebia Therapeutics Inc. (NASDAQ:AKBA) presented mid-stage trial data today not only indicating that its anemia drug helps restore hemoglobin levels, but confirming that it does so in a safe and controlled manner. The Phase 2b trial of 210 patients measured hemoglobin in non-dialysis patients with anemia related to chronic kidney disease. Two-thirds of the patients took Akebia’s experimental drug, AKB-6548, and the others took a placebo.
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) in last trading activity decreased -9.77% to close at $6.74. Company weekly performance is -10.37% while its quarterly performance stands at -15.43%. Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) is -54.28% away from its 52 week high. Bank of America downgraded shares of Himax Technologies Inc. (ADR) (NASDAQ:HIMX) from a buy rating to an underperform rating in a research note released on Tuesday morning.
On last trading day Discover Financial Services (NYSE:DFS) decreased -0.99% to close at $58.91. Its volatility for the week is 1.40% while volatility for the month is 1.41%. DFS’s sales growth for past 5 years was 4.30% and its EPS growth for past 5 years was 32.10%. Discover Financial Services (NYSE:DFS) monthly performance is -1.64%. Discover Financial Services (NYSE:DFS) plans to host a financial community briefing in New York City on Tuesday, May 5, 2015, from 8:30 a.m. to 11:30 a.m. Eastern time. David Nelms, chairman and chief executive officer, and other members of Discover’s senior management team will update the financial community on the company’s performance and business objectives.
On Tuesday shares of Groupon, Inc. (NASDAQ:GRPN) closed at $7.85. Company’s sales growth for last 5 years was 194.10% and EPS growth for next 5 years is recorded as 27.50%. Groupon (NASDAQ:GRPN) announced the appointment of two new executives: Carol Campagnolo to Senior Vice President of Human Resources and Jay Sullivan to Senior Vice President of Consumer Product. Campagnolo will lead Groupon’s global human resources function and will be based in Chicago, reporting to Groupon CEO Eric Lefkofsky.
Gilead Sciences Inc. (NASDAQ:GILD) in last trading activity fell -0.85% to close at $100.44. Company weekly performance is 1.63% while its quarterly performance stands at -3.54%. Gilead Sciences Inc. (NASDAQ:GILD) is -14.03% away from its 52 week high. Drug firm Zydus Cadila launched generic version of Gilead Sciences Inc. (NASDAQ:GILD)’s Hepatitis C drug Sofosbuvir in India under the brand name ‘SoviHep’. “The breakthrough oral therapy ‘SoviHep’ which will provide succour to more than 10 million patients, who suffer from Hepatitis C in India, has been launched by the Zydus Group,” Zydus Cadila said in a BSE filing.